Sermorelin for Women: What the One Sex-Specific Trial Found

This is the most detailed adult trial and the only one in the live research that reported women and men separately. Ten women and nine men aged 55 to 71 self-injected placebo nightly for four weeks, then a norleucine-substituted GHRH(1-29) analogue, a closely related molecule, nightly for sixteen weeks.

IGF-1 and IGFBP-3 rose within two weeks, stayed elevated for twelve, then drifted toward baseline by sixteen. Sleep quality was unchanged. The only adverse effect recorded was a transient lipid rise that resolved by the end of the study.

What it shows. That a GHRH analogue prompts the growth hormone axis in older women as well as men, and that skin thickness changed in both.

What it does not show. That the lean-mass or insulin-sensitivity changes happen in women; in this trial they did not. Nineteen people is a small trial, and nobody has followed up the sex difference. Nothing measured how skin looked.

The rest of the adult evidence was in men or did not report women separately. A 1992 National Institute on Aging study gave healthy older men GHRH(1-29) twice daily and reported IGF-1 rising into the young-adult range only at the higher dose. A 1997 Johns Hopkins trial in eleven men aged 64 to 76 found nocturnal growth hormone rose but IGF-1 did not with single nightly injections. A 2006 trial in Neurobiology of Aging reported that six months of daily GHRH in 89 healthy adults around age 68 was associated with better scores on several cognitive measures; it is one trial, not repeated with sermorelin itself.

The growth hormone axis does not respond identically in women. That is one reason a physician may prefer sermorelin or CJC-1295 / Ipamorelin to a sleep-focused blend when sleep is not the main complaint, and it is a reason not to assume that results reported mainly in men apply to women.

The largest natural growth hormone pulse of the day arrives in slow-wave sleep, and a 2000 paper in JAMA described slow-wave sleep and that pulse declining together across adult life, in healthy men. Sermorelin is dosed at bedtime to add to that pulse. That is the mechanistic rationale, not a trial result: a 2003 review in Endocrine notes that a short-acting GHRH did not improve measured sleep under trial conditions, and in the 1997 trial sleep quality was unchanged. Many people report sleep feeling deeper; that is a report, not a demonstrated outcome.

Waking at 3am is common in perimenopause and after. Night sweats wake people directly, falling progesterone removes a mildly sedating hormone, slow-wave sleep declines with age, and sleep apnea becomes more common after menopause and can present as insomnia rather than snoring. Which of those is driving the waking determines whether a peptide is even the right category of answer. If night sweats are the waker, that is the hormone conversation, not a growth hormone one. Pepti does not prescribe menopausal hormone therapy.

It does not treat hot flashes, night sweats, genitourinary symptoms or bone loss, and it does not replace estrogen. More in peptides for menopause and peptides for women. If sleep is the whole point, DSIP is aimed at it more directly, and peptides for sleep covers the options.

Sermorelin is not used in pregnancy or breastfeeding: there is no safety data, the trials excluded these groups, and there is no clinical reason to accept the uncertainty. There is no human lactation data for sermorelin. Tesamorelin, the one GHRH analogue with an approved label today, is contraindicated in pregnancy, and where one member of a class carries that contraindication, the reading for the rest is not "the others are fine." If you become pregnant on treatment, stop and contact your physician the same day. See can you take peptides while pregnant.

Human fertility outcome data for sermorelin is absent. Growth hormone and IGF-1 signalling interact with reproductive endocrinology, which is a reason for caution rather than a measured effect in either direction. Tell your physician if you are trying. See do peptides affect fertility.

Sermorelin raises growth hormone and IGF-1. No study has shown it causes cancer in humans, though long-term cancer-incidence data for the class do not exist. Growth signalling is avoided with active cancer, and a history, including breast, ovarian or endometrial cancer, is a conversation with your physician and often your oncologist before anything starts.

Growth hormone reduces insulin sensitivity. In the published sermorelin trials fasting glucose was unchanged, but insulin sensitivity tends to worsen through the menopausal transition anyway, so diabetes or impaired glucose tolerance needs discussing at intake.

Sermorelin acts on the growth hormone axis, not the ovarian axis, and no trial has looked at cycle effects in women. Report any cycle change; it is more likely to be the transition than the peptide, but it should be looked at.